• 1. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 2. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 5. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110

Professional Introduction to Compound with CAS No. 151907-80-1 and Product Name: (1R,4S)-4-(tert-butoxycarbonylamino)cyclopent-2-ene-1-carboxylic acid

The compound with the CAS number 151907-80-1 and the product name (1R,4S)-4-(tert-butoxycarbonylamino)cyclopent-2-ene-1-carboxylic acid represents a significant advancement in the field of pharmaceutical chemistry and bioorganic synthesis. This compound, characterized by its chiral cyclopentene core and protected amino group, has garnered considerable attention due to its potential applications in drug development and synthetic methodologies. The stereochemical configuration at the (1R,4S) positions is particularly noteworthy, as it influences the compound's interactions with biological targets and its overall pharmacological profile.

Recent research in the area of heterocyclic compounds has highlighted the importance of cyclopentene derivatives in medicinal chemistry. The presence of a tert-butoxycarbonylamino (Boc) group in this molecule not only provides stability during synthetic transformations but also serves as a versatile handle for further functionalization. This feature is particularly valuable in multi-step synthetic routes where protecting groups play a crucial role in ensuring regioselectivity and minimizing side reactions. The Boc group can be selectively removed under mild acidic conditions, allowing for controlled access to the underlying amine functionality.

One of the most compelling aspects of this compound is its potential utility in the synthesis of chiral building blocks for drug molecules. The cyclopentene scaffold is a common motif in natural products and bioactive compounds, making it an attractive scaffold for medicinal chemists. The (1R,4S) configuration of this compound aligns with the stereochemistry observed in several biologically active molecules, suggesting that it may exhibit similar pharmacological properties. Furthermore, the protected amino group can be later modified into various amine derivatives, such as benzylamines or carbamates, which are prevalent in many drug candidates.

In the context of modern drug discovery, the ability to rapidly access stereodefined building blocks is essential for accelerating the development of novel therapeutics. The synthesis of (1R,4S)-4-(tert-butoxycarbonylamino)cyclopent-2-ene-1-carboxylic acid exemplifies this trend by providing a robust platform for constructing complex molecules. Advances in asymmetric synthesis have enabled more efficient and scalable methods for producing enantiomerically pure compounds like this one. Techniques such as transition-metal-catalyzed reactions and biocatalytic approaches have significantly improved the accessibility of chiral intermediates without relying on traditional chiral auxiliaries.

The versatility of this compound extends beyond its role as a mere building block. Its structural features make it an excellent candidate for exploring new synthetic pathways and methodologies. For instance, the cyclopentene ring can undergo various transformations, including epoxidation, ring-opening reactions, and dihydroxylation, which are pivotal for constructing more complex molecular architectures. Additionally, the presence of both a carboxylic acid and an amine allows for diverse coupling reactions with other functional groups, facilitating the assembly of polyfunctionalized molecules.

Recent studies have also highlighted the importance of computational modeling in rationalizing the reactivity and selectivity of chiral compounds. Molecular modeling techniques can predict how (1R,4S)-4-(tert-butoxycarbonylamino)cyclopent-2-ene-1-carboxylic acid interacts with biological targets at the atomic level. This information is crucial for designing experiments that optimize yield and minimize unwanted side products during synthesis. Furthermore, computational studies can aid in understanding how subtle changes in stereochemistry affect binding affinity and pharmacokinetic properties.

The pharmaceutical industry has increasingly recognized the value of stereochemically complex molecules in drug development. Compounds with multiple stereocenters often exhibit improved efficacy and reduced toxicity compared to their achiral counterparts. The (1R,4S) configuration of this compound places it firmly within this category of high-value intermediates. Its potential applications span across various therapeutic areas, including oncology, immunology, and central nervous system disorders. Researchers are particularly interested in exploring its utility as a precursor for protease inhibitors and kinase inhibitors, which are key targets in modern oncology research.

The synthesis of (1R,4S)-4-(tert-butoxycarbonylamino)cyclopent-2-ene-1-carboxylic acid also underscores the growing importance of sustainable chemistry practices. Green chemistry principles emphasize the need for environmentally benign synthetic routes that minimize waste generation and hazardous exposures. Recent innovations in catalysis and solvent systems have made it possible to produce complex molecules like this one under milder conditions with higher atom economy. These advancements not only improve efficiency but also align with regulatory pressures to reduce environmental impact.

In conclusion,(1R,4S)-4-(tert-butoxycarbonylamino)cyclopent-2-ene-1-carboxylic acid represents a significant contribution to pharmaceutical chemistry and synthetic methodology. Its unique structural features make it a valuable intermediate for constructing complex drug molecules with high stereochemical fidelity. As research continues to uncover new applications for chiral cyclopentene derivatives,CAS No 151907-80-1 will undoubtedly play a pivotal role in future drug development efforts.

• 1060803-66-8(methyl 4-((tert-butoxycarbonyl)amino)cyclopent-2-ene-1-carboxylate)
• 872592-83-1(2-Cyclopentene-1-carboxylic acid,4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-(2-methoxyethyl)-, methylester, (1S,4S)-)
• 229613-91-6(2-Cyclopentene-1-carboxylic acid,4-[[(1,1-dimethylethoxy)carbonyl]amino]-, methyl ester, (1R,4S)-rel-)
• 251326-99-5(methyl (1R,4S)-4-(tert-butoxycarbonylamino)cyclopent-2-ene-1-carboxylate)
• 168683-02-1(methyl (1S,4R)-4-(tert-butoxycarbonylamino)cyclopent-2-ene-1-carboxylate)
• 151907-79-8((1S,4R)-4-(tert-butoxycarbonylamino)cyclopent-2-ene-1-carboxylic acid)
• 298716-03-7((1R,4R)-4-{[(tert-butoxy)carbonyl]amino}cyclopent-2-ene-1-carboxylic acid)
• 108999-93-5(cis-4-((tert-Butoxycarbonyl)amino)cyclopent-2-enecarboxylic acid)
• 624734-31-2(2-Cyclopentene-1-carboxylic acid,4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-(1-methylethyl)-, methyl ester,(1S,4S)-)
• 624734-32-3(2-Cyclopentene-1-carboxylic acid,4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-(1-methylethyl)-, (1S,4S)-)